MEDIROM Healthcare Technologies Past Earnings Performance
Past criteria checks 0/6
MEDIROM Healthcare Technologies's earnings have been declining at an average annual rate of -1.3%, while the Consumer Services industry saw earnings growing at 20.7% annually. Revenues have been growing at an average rate of 29.7% per year.
Key information
-1.3%
Earnings growth rate
1.8%
EPS growth rate
| Consumer Services Industry Growth | 20.3% |
| Revenue growth rate | 29.7% |
| Return on equity | n/a |
| Net Margin | -0.3% |
| Last Earnings Update | 30 Jun 2023 |
Recent past performance updates
Revenue & Expenses Breakdown
How MEDIROM Healthcare Technologies makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 23 | 7,050 | -25 | 1,825 | 0 |
| 31 Mar 23 | 7,002 | 62 | 1,815 | 0 |
| 31 Dec 22 | 6,954 | 149 | 1,805 | 0 |
| 30 Sep 22 | 6,692 | -251 | 1,873 | 0 |
| 30 Jun 22 | 6,429 | -651 | 1,940 | 0 |
| 31 Mar 22 | 5,920 | -821 | 1,875 | 0 |
| 31 Dec 21 | 5,410 | -991 | 1,811 | 0 |
| 30 Sep 21 | 4,761 | -804 | 1,599 | 0 |
| 30 Jun 21 | 4,113 | -618 | 1,388 | 0 |
| 31 Mar 21 | 3,727 | -579 | 1,228 | 0 |
| 31 Dec 20 | 3,342 | -539 | 1,069 | 0 |
| 30 Sep 20 | 3,287 | -509 | 1,025 | 0 |
| 30 Jun 20 | 3,233 | -480 | 982 | 0 |
| 31 Mar 20 | 3,571 | -231 | 927 | 0 |
| 31 Dec 19 | 3,908 | 17 | 872 | 0 |
| 31 Dec 18 | 3,433 | 66 | 843 | 0 |
Quality Earnings: MRM is currently unprofitable.
Growing Profit Margin: MRM is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: MRM is unprofitable, and losses have increased over the past 5 years at a rate of 1.3% per year.
Accelerating Growth: Unable to compare MRM's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MRM is unprofitable, making it difficult to compare its past year earnings growth to the Consumer Services industry (36.8%).
Return on Equity
High ROE: MRM's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.